Chronic hepatitis B infections on the rise since 2008
In 2017, the majority (58%) of the almost 27 000 newly reported hepatitis B cases in the European Union and European Economic Area were classified as chronic infections. This follows a consistent upward trend in reported chronic hepatitis B cases since 2008.
There is evidence of on-going transmission of hepatitis B and continued importation of cases to many European countries according to the available surveillance data for countries of the European Union and the European Economic Area (EU/EEA) for 2017. Incomplete data as well as varying national surveillance systems and practices however impair more detailed epidemiological analysis of reported data.
The majority of EU/EEA countries consistently reporting experienced a steady decline in newly reported acute hepatitis B infections from 1.1 per 100 000 population in 2008 to 0.6 in 2017. This reflects overall global trends and is most likely a result of successful national vaccination programmes: in these countries, the proportion of acute hepatitis B infections among people below 25 years of age declined from 20% in 2008 to 12% in 2017. The proportion of chronic cases under 25 declined from 21% in 2008 to 10% in 2017.
However, during the same time period notifications of chronic hepatitis B overall increased from 6.7 per 100 000 population to 10.2 in 2017 with the highest rates reported among the 25–34-year-olds. Overall, the reported data on chronic hepatitis B seems to mirror the intensity of local testing and screening policies – thus countries with comprehensive testing programmes in place appear to have the highest notification rates. The high number of chronic infections from northern Europe has a strong influence on trends with e.g. 62% of chronic hepatitis B cases in 2017 notified by the United Kingdom.
Incomplete data affects interpretation
Transmission data are key to understanding the epidemiology of hepatitis B. However, information on the transmission mode was only complete for roughly a third (29%) of the reported acute cases in 2017 and only 13% of the notified chronic cases. Hence, data are unlikely to be fully representative, and observed trends and differences between countries are hard to interpret.
For the 718 acute cases with complete information, heterosexual transmission was most commonly reported (27%), followed by nosocomial transmission (16%), sex between men (13%), non-occupational injuries (10%) and injecting drug use (10%). Italy, Poland and Romania accounted for 74% of the acute cases attributed to healthcare-associated hepatitis B infections in 2017.
Where this information was available, transmission from mother to child and in healthcare settings were the most commonly reported routes for chronic hepatitis B infection (41% and 28% respectively). Poland reported 90% of chronic cases related to nosocomial transmission.
Of the 12 018 cases (45%) with information on importation status, 3 778 (31%) were reported as imported. The influence of migration on hepatitis B epidemiology highlights the need for countries to develop evidence-based screening interventions that target the most affected migrant communities. It also highlights the importance of monitoring routine surveillance indicators of migration, such as importation status.
The relatively high number of 26 907 reported hepatitis B infections in 2017and especially chronic cases, in combination with the diversity in reported transmission routes across Europe suggest that countries need to maintain and strengthen local hepatitis prevention and control programmes.
The World Health Organization’s European Action plan for the health sector response to viral hepatitis outlines ways to do this. Based on the information from the ECDC prevalence database, authorities can identify the key population groups and areas of high hepatitis prevalence for targeted efforts.
ECDC rolled out a monitoring framework to support EU/EEA countries in their efforts to implement hepatitis B and C control programmes. This system will provide a comprehensive and much needed overview of the progress in tackling these infections and allows for a clearer picture of the actual burden of disease.
Latest News from
EC opens investigation into possible anti-competitive conduct of Amazon18/07/2019 15:25:00
The EC has opened a formal antitrust investigation to assess whether Amazon's use of sensitive data from independent retailers who sell on its marketplace is in breach of EU competition rules.
Turkish drilling activities in the Eastern Mediterranean16/07/2019 15:25:00
The Council adopted the following conclusions on the Turkish drilling activities in the Eastern Mediterranean.
Four new substances added to the Candidate List16/07/2019 13:43:00
The Candidate List of substances of very high concern (SVHCs) for authorisation now contains 201 substances.
Imports of hormone-free beef: EU-US agreement confirmed16/07/2019 11:43:00
The Council has adopted a decision on the signing of an agreement between the EU and the US on the allocation to the US of a share in the TRQ for high quality beef regarding the importation of beef from animals not treated with certain growth-promoting hormones.
EIOPA consults on the harmonisation of national insurance guarantee schemes15/07/2019 12:32:00
Tthe European Insurance and Occupational Pension Authority (EIOPA) has launched a consultation on its Advice on the harmonisation of national insurance guarantee schemes across the Member States of the European Union.
EU-U.S. trade talks: milestone reached in mutual recognition on pharmaceuticals12/07/2019 15:25:00
The EU and the USA have delivered on a significant element of the Joint Statement agreed by Presidents Juncker and Trump in July 2018. The positive transatlantic trade agenda established in the Joint Statement includes a commitment from both sides to reduce barriers and increase trade in a range of sectors, including pharmaceuticals.
Airbnb cooperates with EC and EU consumer authorities improving the way it presents offers12/07/2019 13:25:00
The EC has announced that, as a result of negotiations with Airbnb, the platform has improved and fully clarified the way it presents accommodation offers to consumers, which is now in line with the standards set in EU consumer law.
European Institute of Innovation and Technology: EC proposes strategy for 2021-202712/07/2019 11:33:00
The EC has proposed an update of the legal base of the European Institute of Innovation and Technology (EIT) as well as its new Strategic Innovation Agenda for 2021-2027.
EC approves GlaxoSmithKline's acquisition of Pfizer's Consumer Health Business with conditions11/07/2019 15:25:00
The EC has approved, under the EU Merger Regulation, the acquisition of Pfizer's Consumer Health Business by GlaxoSmithKline. The decision is conditional upon the global divestment of Pfizer's topical pain management business carried out under the ThermaCare brand.